Ranibizumab leading the anti-VEGF evolution
Considerations and new perspectives in anti-VEGF therapy.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
The ZEISS IOL Power Calculation Service. Providing guidance in complex cases
January 15th 2025Article
Advances in biometric technology and IOL calculation formulas have enabled refractive accuracy of cataract and clear lens exchange (CLE) surgery, but IOL power selection remains challenging in some cases. I have found that the ZEISS IOL Power Calculation Service (IPCS) is a valuable asset to help me in these uncertain situations.
